Stuttgart - Delayed Quote EUR
Neuren Pharmaceuticals Ltd (NK9.SG)
6.25
+0.05
+(0.81%)
At close: April 25 at 8:04:04 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
213,243
213,243
231,925
14,553
--
Gross Profit
213,243
213,243
231,925
14,553
--
Operating Expense
37,693
37,693
32,714
16,159
11,438
Operating Income
175,550
175,550
199,211
-1,606
-11,438
Net Non Operating Interest Income Expense
11,014
11,014
5,687
391
41
Other Income Expense
-3,646
-3,646
225
1,389
3,595
Pretax Income
182,940
182,940
205,140
184
-7,794
Tax Provision
40,897
40,897
48,059
--
--
Net Income Common Stockholders
142,043
142,043
157,081
184
-7,794
Basic EPS
0.65
1.11
1.24
0.00
-0.07
Diluted EPS
0.63
1.09
1.20
0.00
-0.07
Basic Average Shares
127,623.69
127,769.43
127,069.51
125,965.68
117,770.05
Diluted Average Shares
132,892.36
130,782.62
130,791.84
125,965.68
117,770.05
Net Income from Continuing & Discontinued Operation
142,043
142,043
157,081
184
-7,794
Normalized Income
142,043
142,043
157,081
184
-7,794
Interest Income
11,014
11,014
5,687
391
41
Net Interest Income
11,014
11,014
5,687
391
41
EBIT
175,550
175,550
199,211
-1,606
-11,438
EBITDA
175,572
175,572
199,228
-1,596
-11,430
Reconciled Depreciation
22
22
17
10
8
Net Income from Continuing Operation Net Minority Interest
142,043
142,043
157,081
184
-7,794
Normalized EBITDA
175,572
175,572
199,228
-1,596
-11,430
Tax Rate for Calcs
0
0
0
--
--
12/31/2021 - 8/5/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade